The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.58 billion in 2025 to $0.66 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to expansion of cancer genomics research, increased availability of sequencing platforms, growth in oncology clinical trials, rising adoption of molecular diagnostics, declining sequencing costs.
The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $1.04 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing demand for precision oncology, rising investments in genomic medicine, expansion of hospital-based sequencing laboratories, growing use of targeted cancer therapies, continuous advancements in sequencing technologies. Major trends in the forecast period include increasing adoption of ngs-based oncology diagnostics, rising use of companion diagnostic applications, growing integration of bioinformatics and data analytics, expansion of personalized cancer treatment approaches, enhanced focus on rare mutation detection.
The rising prevalence of cancer is expected to drive the growth of the clinical oncology next-generation sequencing (NGS) market. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. NGS plays a vital role in detecting novel and rare mutations in cancer, helping to better understand the molecular foundations of individual tumors. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that there were approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Therefore, the growing prevalence of cancer is a major factor driving the expansion of the clinical oncology next-generation sequencing market.
Major companies operating in the clinical oncology next-generation sequencing (NGS) market are emphasizing technological advancements, including the integration of software accelerators that significantly cut the time and cost associated with secondary NGS analysis, allowing laboratories to generate results more rapidly while reducing computational resource requirements. These accelerator solutions enable comprehensive genomic profiling and improve the accessibility of high-throughput cancer panels for both large centralized laboratories and decentralized diagnostic environments. For instance, in January 2024, QIAGEN Digital Insights, a Germany-based bioinformatics company, introduced an upgraded version of its CLC Genomics Workbench Premium incorporating LightSpeed technology with support for somatic cancer secondary analysis. The LightSpeed accelerator is capable of processing a 275-gene cancer panel at 3377× coverage in approximately six minutes, at a cost of less than US$0.72 per test in standard cloud settings. LightSpeed is designed to deliver high performance and accuracy with lower power consumption and does not require new hardware or additional licenses beyond the existing CLC platform.
In January 2023, Agilent Technologies, a US-based scientific equipment manufacturer, acquired Avida Biomed for an undisclosed amount. This acquisition aims to strengthen Agilent Technologies' high-performance target enrichment workflows for next-generation sequencing applications, particularly in cancer research. By integrating Avida's innovative technologies, Agilent seeks to enhance precision medicine approaches and expand its SureSelect portfolio into the clinical research and diagnostics markets. Avida Biomed, a US-based biotechnology company, specializes in clinical oncology next-generation sequencing.
Major companies operating in the clinical oncology next generation sequencing market are Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.
North America was the largest region in the clinical oncology next-generation sequencing market in 2025. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the clinical oncology next generation sequencing market by increasing costs of imported sequencing instruments, reagents, flow cells, chips, and advanced bioinformatics hardware. Hospital laboratories and research institutions in North America and Europe are most affected due to reliance on imported sequencing platforms, while Asia-Pacific faces cost pressure on instrument manufacturing and reagent supply. These tariffs are raising operational costs and slowing technology upgrades. However, they are also encouraging regional production of sequencing consumables, domestic instrument assembly, and development of localized genomic analysis solutions.
The clinical oncology next generation sequencing market research report is one of a series of new reports that provides clinical oncology next generation sequencing market statistics, including clinical oncology next generation sequencing industry global market size, regional shares, competitors with a clinical oncology next generation sequencing market share, detailed clinical oncology next generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next generation sequencing industry. This clinical oncology next generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Next generation sequencing (NGS) is a method employed to determine the sequence of nucleotides within a segment of DNA and is commonly utilized in oncology research. NGS plays a crucial role in identifying rare cancer mutations, detecting carriers of familial cancer mutations, and providing the molecular basis for targeted therapy.
The primary technologies in clinical oncology NGS encompass ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a sequencing technique based on the detection of hydrogen ions released during DNA polymerization. Clinical oncology NGS finds applications in various areas, including screening, companion diagnostics, and other diagnostic purposes, and it is used by a range of end-users, including hospital laboratories, clinical research organizations, and diagnostic laboratories.
The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $1.04 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to increasing demand for precision oncology, rising investments in genomic medicine, expansion of hospital-based sequencing laboratories, growing use of targeted cancer therapies, continuous advancements in sequencing technologies. Major trends in the forecast period include increasing adoption of ngs-based oncology diagnostics, rising use of companion diagnostic applications, growing integration of bioinformatics and data analytics, expansion of personalized cancer treatment approaches, enhanced focus on rare mutation detection.
The rising prevalence of cancer is expected to drive the growth of the clinical oncology next-generation sequencing (NGS) market. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. NGS plays a vital role in detecting novel and rare mutations in cancer, helping to better understand the molecular foundations of individual tumors. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that there were approximately 18.1 million cancer survivors in the United States. This number is projected to increase to 22.5 million by 2032. By 2040, the number of new cancer cases annually is expected to reach 29.9 million, with cancer-related deaths estimated to rise to 15.3 million. Therefore, the growing prevalence of cancer is a major factor driving the expansion of the clinical oncology next-generation sequencing market.
Major companies operating in the clinical oncology next-generation sequencing (NGS) market are emphasizing technological advancements, including the integration of software accelerators that significantly cut the time and cost associated with secondary NGS analysis, allowing laboratories to generate results more rapidly while reducing computational resource requirements. These accelerator solutions enable comprehensive genomic profiling and improve the accessibility of high-throughput cancer panels for both large centralized laboratories and decentralized diagnostic environments. For instance, in January 2024, QIAGEN Digital Insights, a Germany-based bioinformatics company, introduced an upgraded version of its CLC Genomics Workbench Premium incorporating LightSpeed technology with support for somatic cancer secondary analysis. The LightSpeed accelerator is capable of processing a 275-gene cancer panel at 3377× coverage in approximately six minutes, at a cost of less than US$0.72 per test in standard cloud settings. LightSpeed is designed to deliver high performance and accuracy with lower power consumption and does not require new hardware or additional licenses beyond the existing CLC platform.
In January 2023, Agilent Technologies, a US-based scientific equipment manufacturer, acquired Avida Biomed for an undisclosed amount. This acquisition aims to strengthen Agilent Technologies' high-performance target enrichment workflows for next-generation sequencing applications, particularly in cancer research. By integrating Avida's innovative technologies, Agilent seeks to enhance precision medicine approaches and expand its SureSelect portfolio into the clinical research and diagnostics markets. Avida Biomed, a US-based biotechnology company, specializes in clinical oncology next-generation sequencing.
Major companies operating in the clinical oncology next generation sequencing market are Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.
North America was the largest region in the clinical oncology next-generation sequencing market in 2025. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the clinical oncology next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the clinical oncology next generation sequencing market by increasing costs of imported sequencing instruments, reagents, flow cells, chips, and advanced bioinformatics hardware. Hospital laboratories and research institutions in North America and Europe are most affected due to reliance on imported sequencing platforms, while Asia-Pacific faces cost pressure on instrument manufacturing and reagent supply. These tariffs are raising operational costs and slowing technology upgrades. However, they are also encouraging regional production of sequencing consumables, domestic instrument assembly, and development of localized genomic analysis solutions.
The clinical oncology next generation sequencing market research report is one of a series of new reports that provides clinical oncology next generation sequencing market statistics, including clinical oncology next generation sequencing industry global market size, regional shares, competitors with a clinical oncology next generation sequencing market share, detailed clinical oncology next generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the clinical oncology next generation sequencing industry. This clinical oncology next generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Next generation sequencing (NGS) is a method employed to determine the sequence of nucleotides within a segment of DNA and is commonly utilized in oncology research. NGS plays a crucial role in identifying rare cancer mutations, detecting carriers of familial cancer mutations, and providing the molecular basis for targeted therapy.
The primary technologies in clinical oncology NGS encompass ion semiconductor sequencing, pyro-sequencing, synthesis sequencing, real-time sequencing, ligation sequencing, reversible dye termination sequencing, and nanopore sequencing. Ion semiconductor sequencing is a sequencing technique based on the detection of hydrogen ions released during DNA polymerization. Clinical oncology NGS finds applications in various areas, including screening, companion diagnostics, and other diagnostic purposes, and it is used by a range of end-users, including hospital laboratories, clinical research organizations, and diagnostic laboratories.
The clinical oncology next-generation sequencing market consists of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductors sequencing, pyro-sequencing, synthesis sequencing (SBS), real-time sequencing (SMRT), ligation sequencing, and other techniques that are used in oncology research for determining the nucleotide sequence leading to clinical oncology. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Clinical Oncology Next Generation Sequencing Market Characteristics
3. Clinical Oncology Next Generation Sequencing Market Supply Chain Analysis
4. Global Clinical Oncology Next Generation Sequencing Market Trends and Strategies
5. Clinical Oncology Next Generation Sequencing Market Analysis of End Use Industries
7. Global Clinical Oncology Next Generation Sequencing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Clinical Oncology Next Generation Sequencing Total Addressable Market (TAM) Analysis for the Market
9. Clinical Oncology Next Generation Sequencing Market Segmentation
454 Pyrosequencing, Other Pyro-Sequencing Technologies
10. Clinical Oncology Next Generation Sequencing Market Regional and Country Analysis
11. Asia-Pacific Clinical Oncology Next Generation Sequencing Market
12. China Clinical Oncology Next Generation Sequencing Market
13. India Clinical Oncology Next Generation Sequencing Market
14. Japan Clinical Oncology Next Generation Sequencing Market
15. Australia Clinical Oncology Next Generation Sequencing Market
16. Indonesia Clinical Oncology Next Generation Sequencing Market
17. South Korea Clinical Oncology Next Generation Sequencing Market
18. Taiwan Clinical Oncology Next Generation Sequencing Market
19. South East Asia Clinical Oncology Next Generation Sequencing Market
20. Western Europe Clinical Oncology Next Generation Sequencing Market
21. UK Clinical Oncology Next Generation Sequencing Market
22. Germany Clinical Oncology Next Generation Sequencing Market
23. France Clinical Oncology Next Generation Sequencing Market
24. Italy Clinical Oncology Next Generation Sequencing Market
25. Spain Clinical Oncology Next Generation Sequencing Market
26. Eastern Europe Clinical Oncology Next Generation Sequencing Market
27. Russia Clinical Oncology Next Generation Sequencing Market
28. North America Clinical Oncology Next Generation Sequencing Market
29. USA Clinical Oncology Next Generation Sequencing Market
30. Canada Clinical Oncology Next Generation Sequencing Market
31. South America Clinical Oncology Next Generation Sequencing Market
32. Brazil Clinical Oncology Next Generation Sequencing Market
33. Middle East Clinical Oncology Next Generation Sequencing Market
34. Africa Clinical Oncology Next Generation Sequencing Market
36. Clinical Oncology Next Generation Sequencing Market Competitive Landscape and Company Profiles
37. Clinical Oncology Next Generation Sequencing Market Other Major and Innovative Companies
40. Clinical Oncology Next Generation Sequencing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Clinical Oncology Next Generation Sequencing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses clinical oncology next generation sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for clinical oncology next generation sequencing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The clinical oncology next generation sequencing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Technology: Ion Semiconductor Sequencing; Pyro-Sequencing; Synthesis Sequencing; Real Time Sequencing; Ligation Sequencing; Reversible Dye Termination Sequencing; Nano-Pore Sequencing2) By Application: Screening; Companion Diagnostics; Other Diagnostics
3) By End User: Hospital Laboratories; Clinical Research Organizations; Diagnostic Laboratories
Subsegments:
1) By Ion Semiconductor Sequencing: Ion Proton System; Ion PGM System; Ion S5 System; Other Ion Semiconductor Sequencing Technologies2) By Pyro-Sequencing: 454 Pyrosequencing; Other Pyro-Sequencing Technologies
3) By Synthesis Sequencing: Illumina Sequencing Technology; SOLiD Sequencing Technology; Other Synthesis Sequencing Technologies
4) By Real-Time Sequencing: PacBio RS II System; Sequel System; Other Real-Time Sequencing Technologies
5) By Ligation Sequencing: Helicos Single Molecule Sequencing; Other Ligation Sequencing Technologies
6) By Reversible Dye Termination Sequencing: Illumina HiSeq; Illumina NextSeq; Other Reversible Dye Termination Sequencing Technologies
7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION); Other Nano-Pore Sequencing Technologies
Companies Mentioned: Thermo Fisher Scientific; Oxford Nanopore Technologies Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; Illumina Inc.; F. Hoffmann-La Roche Ltd.; PerkinElmer Inc.; Agilent Technologies Inc.; Pacific Biosciences of California Inc.; Caris Life Sciences; Paradigm Diagnostics; GATC Biotech AG; Macrogen Inc.; DNASTAR Inc.; Exosome Diagnostics Inc.; Biomatters Ltd.; Partek Inc.; Foundation Medicine Inc.; Becton Dickinson and Company (BD); Takara Bio Inc.; Knome Inc.; Genomatix Software GmbH; CLC bio; GnuBIO Inc.; Bio-Rad Laboratories Inc.; BGI Genomics Co. Ltd.; Guardant Health Inc.; Invitae Corporation; Natera Inc.; NeoGenomics Laboratories Inc.; Sysmex Corporation; Veracyte Inc.; Zymo Research Corporation; ArcherDX Inc.; Karius Inc.; OncoDNA S.A.; Personal Genome Diagnostics Inc.; PierianDx Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Clinical Oncology Next Generation Sequencing market report include:- Thermo Fisher Scientific
- Oxford Nanopore Technologies Ltd.
- QIAGEN N.V.
- Myriad Genetics Inc.
- Illumina Inc.
- F. Hoffmann-La Roche Ltd.
- PerkinElmer Inc.
- Agilent Technologies Inc.
- Pacific Biosciences of California Inc.
- Caris Life Sciences
- Paradigm Diagnostics
- GATC Biotech AG
- Macrogen Inc.
- DNASTAR Inc.
- Exosome Diagnostics Inc.
- Biomatters Ltd.
- Partek Inc.
- Foundation Medicine Inc.
- Becton Dickinson and Company (BD)
- Takara Bio Inc.
- Knome Inc.
- Genomatix Software GmbH
- CLC bio
- GnuBIO Inc.
- Bio-Rad Laboratories Inc.
- BGI Genomics Co. Ltd.
- Guardant Health Inc.
- Invitae Corporation
- Natera Inc.
- NeoGenomics Laboratories Inc.
- Sysmex Corporation
- Veracyte Inc.
- Zymo Research Corporation
- ArcherDX Inc.
- Karius Inc.
- OncoDNA S.A.
- Personal Genome Diagnostics Inc.
- PierianDx Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.66 Billion |
| Forecasted Market Value ( USD | $ 1.04 Billion |
| Compound Annual Growth Rate | 12.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 39 |
